In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on GH Research (GHRS – Research Report), with a price ...

JMP Securities reiterated its Market Outperform rating on AN2 Therapeutics (NASDAQ:ANTX) shares, maintaining a $5.00 price target, representing significant upside from the current price of $1.14.

In a report released today, Matthew Condon from JMP Securities reiterated a Buy rating on Roku (ROKU – Research Report), with a price target of ...

JMP Securities reaffirmed its Market Outperform rating on Roku Inc. (NASDAQ:ROKU) with a steady price target of $95.00. According to InvestingPro data, Roku's stock has shown significant momentum with ...

Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...

JMP Securities analyst Silvan Tuerkcan initiated coverage of Solid Biosciences (SLDB) with an Outperform rating and $15 price target Solid is a clinical-stage biotechnology company focused on ...

Fintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Market Outperform recommendation. As of January 28, 2025, the average ...

Narwhal Capital Management acquired a new stake in Alphabet Inc. (NASDAQ:GOOGL – Free Report) in the fourth quarter, ...

Investing.com -- JMP Securities initiated coverage on digital infrastructure companies on AI related spending boom. Over the next five years, over $1 trillion in investments is expected ...

JMP Securities raised the price targets on Cloudflare (NET) and CyberArk Software (CYBR), while highlighting an industry ...

JMP Securities analyst Constantine Davides raised the firm’s price target on Option Care Health (OPCH) to $35 from $30 and ...

On Friday, JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a price target of $26.00. The stock, currently trading at $7.49, ...